Filter
159
Filtered Results: 159
Text search:
omicron
Featured
Recommendations
28
New Publications
6
Language
Document type
Guidelines
57
Studies & Reports
33
Fact sheets
18
Strategic & Response Plan
14
Situation Updates
10
No document type
9
Training Material
7
Manuals
6
Infographics
3
Videos
2
Countries / Regions
Latin America and the Carribbean
9
Brazil
9
Global
8
Africa
5
Kenya
4
Mozambique
4
Ukraine
3
Argentina
3
Syria
2
Philippines
2
Germany
2
South Africa
2
Ethiopia
2
El Salvador
1
Turkey
1
Sierra Leone
1
Nigeria
1
Senegal
1
Burundi
1
Peru
1
Asia
1
Venezuela
1
Jordan
1
Western Pacific Region
1
Eastern Europe and Central Asia
1
Western and Central Europe
1
Southern Africa
1
Lebanon
1
Eastern Europe
1
Moldova
1
Russia
1
Namibia
1
Egypt
1
Angola
1
Chad
1
South Sudan
1
Iraq
1
Liberia
1
India
1
Myanmar / Burma
1
Authors & Publishers
Publication Years
Category
Countries
56
Women & Child Health
8
Public Health
7
Key Resources
7
Clinical Guidelines
5
Capacity Building
3
Pharmacy & Technologies
2
Annual Report MEDBOX
1
Toolboxes
COVID-19
88
Caregiver
8
Planetary Health
8
Refugee
6
Conflict
6
Health Financing Toolbox
4
Mental Health
3
TB
3
Global Health Education
3
Natural Hazards
2
Disability
2
Pharmacy
2
NCDs
2
NTDs
1
Malaria
1
Polio
1
AMR
1
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022
Situation report generated by the OPS/WHO representation in Argentina
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to finance equitable access in 92 lower-income countries. Si...
26 de abril del 2022. La Organización Panamericana de la Salud presenta estas consideraciones con el fin de apoyar la toma de decisiones relativa al manejo de pacientes con COVID-19 en la Región de las Américas. Las recomendaciones tienen en cuenta la evidencia más reciente, el estado de vacunac...
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
More than two years since the first SARS-CoV-2 infections were reported, the COVID-19 pandemic remains an acute global emergency. In this Strategic Preparedness, Readiness and Response plan for 2022, WHO sets out a number of key strategic adjustments that, if implemented rapidly and consistently at ...
The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19.
The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID...
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so...
Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline
recommended
This second edition of the Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline provides the most up to date technical guidance on mask use in community settings in the context of COVID-19.
In this edition, new information includes updated mask re...
an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, latest update: 21 January 2022
Available in English, F...
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
New funding requirements: CHF 2.8 billion IFRC-wide of which CHF 670 million is channelled through the IFRC Emergency Appeal in support of National Societies
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
